Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Access the Market Tools Trusted by Thousands of Investors Get Started
Allergan to buy Tobira in push for NASH treatments
Published Sep 20, 2016 09:04AM ET
© Reuters. The Allergan logo is seen in this photo illustration
(Reuters) - Allergan Plc (N:AGN) said it would buy Tobira Therapeutics Inc (O:TBRA) in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease.
Allergan's offer of $28.35 per Tobira share upfront is nearly a whopping 500 percent premium to the stock's close on Monday, which gave Tobira a market capitalization of about $89 million.
Dublin-based Allergan said Tobira shareholders could get up to $49.84 per share contingent on the company achieving certain milestones.
Tobira's shares surged 575 percent to $32 premarket on Tuesday. Allergan's shares were off 0.4 percent.
This is the latest in a string of deals orchestrated by Brent Saunders, Allergan's chief executive and a seasoned dealmaker.
About 30 percent of people in the United States suffer from fatty liver diseases such as NASH (nonalcoholic steatohepatitis) due to obesity, diabetes and over-indulgent lifestyles, according to the American Liver Foundation.
NASH, which occurs in up to 5 percent of Americans, is a silent liver disease that resembles alcoholic liver disease, but occurs in people who drink little or no alcohol.
There are no approved medicines for NASH. Without treatment, sufferers can develop advanced damage, including the scarring known as fibrosis; cirrhosis, which destroys liver function; and even cancer.
Other major contenders in the race to develop a drug to treat NASH include Intercept Pharmaceuticals Inc (O:ICPT) and Genfit SA (PA:GNFT), who have drugs in late-stage development.
Conatus Pharmaceuticals Inc's (O:CNAT) treatment is in mid-stage development.
Covington & Burling are Allergan's lead legal counsel. Centerview Partners and Citi are Tobira's financial advisers, while Skadden, Arps, Slate, Meagher & Flom LLP and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP are its legal counsel.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.